Health Catalyst, Inc. HCAT
1.45 USD +0.01 (+0.69%)
Nov 11, 2026, 11:15 AM EST
1.41 Day range 1.50
0.955 52-week range 3.03
- YTD
- -39.33%
- 1 year
- -46.10%
News
seekingalpha.com Health Catalyst, Inc. (HCAT) Q3 2026 Earnings Call Transcript Health Catalyst, Inc. ( HCAT ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Stephanie St Clair - Senior Vice President of Finance & Investor Relations Simeon Kohl - CEO,…
marketbeat.com What Health Catalyst (HCAT) Said on Its Q3 Earnings Call Health Catalyst NASDAQ: HCAT reported third-quarter revenue and adjusted EBITDA above its guidance ranges, but executives said client churn and cost pressures remain challenges as the healthcare…
zacks.com Health Catalyst (HCAT) Reports Q3 Loss, Beats Revenue Estimates Health Catalyst (HCAT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.06 per share a year ago.
zacks.com Here's What Key Metrics Tell Us About Health Catalyst (HCAT) Q3 Earnings While the top- and bottom-line numbers for Health Catalyst (HCAT) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key…
benzinga.com Health Catalyst Q3 2026 Earnings Call Transcript Health Catalyst (NASDAQ:HCAT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Health Catalyst Affirms FY2026 Sales Guidance of $246.000M-$249.000M vs $247.804M Est Health Catalyst (NASDAQ:HCAT) affirms FY2026 sales outlook from $246.000 million-$249.000 million to $246.000 million-$249.000 million vs $247.804 million estimate.
benzinga.com Health Catalyst Q3 Adj. EPS $(0.03) Beats $(0.05) Estimate, Sales $56.283M Beat $55.390M Estimate Health Catalyst (NASDAQ:HCAT) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.05) by 40 percent. This is a 150 percent decrease over earnings of $0.06…
globenewswire.com Health Catalyst Reports Third Quarter 2026 Results SALT LAKE CITY, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health…
benzinga.com Health Catalyst Reports Q2 2026 Results: Full Earnings Call Transcript Health Catalyst (NASDAQ:HCAT) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call…
benzinga.com This Teradyne Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday Wall Street analysts changed ratings for top stocks. See full list at Benzinga's analyst ratings page. TER, TX and more.- benzinga.com Canaccord Genuity Downgrades Health Catalyst to Hold, Lowers Price Target to $1.8 Canaccord Genuity analyst Richard Close downgrades Health Catalyst (NASDAQ:HCAT) from Buy to Hold and lowers the price target from $3 to $1.8.
benzinga.com Wells Fargo Maintains Equal-Weight on Health Catalyst, Lowers Price Target to $1.5 Wells Fargo analyst Stan Berenshteyn maintains Health Catalyst (NASDAQ:HCAT) with a Equal-Weight and lowers the price target from $1.75 to $1.5.
benzinga.com Citigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $2 Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ:HCAT) with a Neutral and lowers the price target from $2.5 to $2.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session. The company's market cap stands at $146.1 million. As per the press release, Q2 earnings came out…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The market value of their outstanding shares is at $3.7 billion. As per the news, the Q1 earnings report…
benzinga.com Why Atlassian Shares Are Trading Higher By More Than 30%; Here Are 20 Stocks Moving Premarket Atlassian Corp (NASDAQ: TEAM) reported strong Q4 results, beating revenue and earnings estimates. Stock jumped 30.7% in pre-market trading.
benzinga.com Health Catalyst Shares Tumble Overnight: What Investors Need to Know Health Catalyst stock fell after hours after reporting Q2 results and issuing weaker third-quarter revenue guidance.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market session. The market value of their outstanding shares is at $3.8 billion. The company's, Q1 earnings…
benzinga.com Health Catalyst Sees FY2026 Sales $246.000M-$249.000M vs $260.780M Est Health Catalyst (NASDAQ:HCAT) sees FY2026 sales of $246.000 million-$249.000 million vs $260.780 million analyst estimate.
benzinga.com Health Catalyst Q2 Adj. EPS $0.04 Beats $0.03 Estimate, Sales $70.487M Beat $69.059M Estimate Health Catalyst (NASDAQ:HCAT) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.03 by 33.33 percent. This is unchanged from the same period last year. The…
benzinga.com Canaccord Genuity Maintains Buy on Health Catalyst, Raises Price Target to $3 Canaccord Genuity analyst Richard Close maintains Health Catalyst (NASDAQ:HCAT) with a Buy and raises the price target from $2 to $3.- benzinga.com Wells Fargo Maintains Equal-Weight on Health Catalyst, Raises Price Target to $1.75 Wells Fargo analyst Stan Berenshteyn maintains Health Catalyst (NASDAQ:HCAT) with a Equal-Weight and raises the price target from $1 to $1.75.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com Health Catalyst Agrees To Divest Vitalware And Vitalware Business Unit To Med-Metrix For Total Consideration Of $147M In Cash Health Catalyst, Inc. (("Health Catalyst" or the "Company, NASDAQ:HCAT) today announced it has signed a definitive agreement to divest Vitalware, LLC and the Vitalware business unit, its mid-revenue…
- benzinga.com Stephens & Co. Maintains Equal-Weight on Health Catalyst, Lowers Price Target to $1.75 Stephens & Co. analyst Jeff Garro maintains Health Catalyst (NASDAQ:HCAT) with a Equal-Weight and lowers the price target from $2 to $1.75.
- benzinga.com Health Catalyst Q1 Adj. EPS $0.02, Inline, Sales $70.756M Beat $69.171M Estimate Health Catalyst (NASDAQ:HCAT) reported quarterly earnings of $0.02 per share which met the analyst consensus estimate. This is a 100 percent increase over earnings of $0.01 per share from the same…
benzinga.com Earnings Scheduled For May 11, 2026 - benzinga.com Health Catalyst Eliminates Chief People Officer Role, Cuts ~9% Workforce, Or ~100 Positions, Under Cost-Reduction Initiative 'Project Nexus' Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 24, 2026, the Board of Directors (our…
- benzinga.com Wells Fargo Downgrades Health Catalyst to Equal-Weight, Lowers Price Target to $1 Wells Fargo analyst Stan Berenshteyn downgrades Health Catalyst (NASDAQ:HCAT) from Overweight to Equal-Weight and lowers the price target from $5 to $1.
- benzinga.com Citigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $1.75 Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ:HCAT) with a Neutral and lowers the price target from $2.75 to $1.75.
benzinga.com Canaccord Genuity Maintains Buy on Health Catalyst, Lowers Price Target to $2 Canaccord Genuity analyst Richard Close maintains Health Catalyst (NASDAQ:HCAT) with a Buy and lowers the price target from $5 to $2.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session - benzinga.com Stephens & Co. Maintains Equal-Weight on Health Catalyst, Lowers Price Target to $2 Stephens & Co. analyst Jeff Garro maintains Health Catalyst (NASDAQ:HCAT) with a Equal-Weight and lowers the price target from $3.5 to $2.
- benzinga.com Stifel Maintains Hold on Health Catalyst, Lowers Price Target to $2 Stifel analyst David Grossman maintains Health Catalyst (NASDAQ:HCAT) with a Hold and lowers the price target from $3.75 to $2.
- benzinga.com Cantor Fitzgerald Maintains Neutral on Health Catalyst, Lowers Price Target to $3 Cantor Fitzgerald analyst Sarah James maintains Health Catalyst (NASDAQ:HCAT) with a Neutral and lowers the price target from $4 to $3.
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Health Catalyst Q4 Adj. EPS $0.08 Misses $0.09 Estimate, Sales $74.679M Beat $73.984M Estimate Health Catalyst (NASDAQ:HCAT) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.09 by 12.09 percent. This is a 100 percent increase over earnings of…
- benzinga.com Earnings Scheduled For March 12, 2026
benzinga.com Health Catalyst Appoints Ben Albert As CEO, Succeeding Dan Burton Albert to Sharpen Focus on Improving Cost and Operational Efficiency,Clinical Quality, and Consumer Experience in HealthcareHealth Catalyst Board to be Reduced to Five DirectorsImmediately Prior to…
benzinga.com 4 Analysts Have This To Say About Health Catalyst - benzinga.com Citigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $2.75 Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ:HCAT) with a Neutral and lowers the price target from $3.25 to $2.75.
- benzinga.com Citigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $3.25 Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ:HCAT) with a Neutral and lowers the price target from $3.5 to $3.25.
- benzinga.com Stifel Maintains Hold on Health Catalyst, Lowers Price Target to $3.75 Stifel analyst David Grossman maintains Health Catalyst (NASDAQ:HCAT) with a Hold and lowers the price target from $4.5 to $3.75.
- benzinga.com Wells Fargo Maintains Overweight on Health Catalyst, Lowers Price Target to $5 Wells Fargo analyst Stan Berenshteyn maintains Health Catalyst (NASDAQ:HCAT) with a Overweight and lowers the price target from $6 to $5.
- benzinga.com Health Catalyst's Twistle By Health Catalyst, Lumeon By Health Catalyst, And Upfront By Health Catalyst Achieve HITRUST r2 Certification Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Twistle by Health Catalyst…
- benzinga.com Health Catalyst Affirms FY2025 Sales Guidance of $310.000M vs $312.152M Est Health Catalyst (NASDAQ:HCAT) affirms FY2025 sales outlook from $310.000 million to $310.000 million vs $312.152 million estimate.
- benzinga.com Health Catalyst Q3 Adj. EPS $0.06, Inline, Sales $76.323M Beat $75.900M Estimate Health Catalyst (NASDAQ:HCAT) reported quarterly earnings of $0.06 per share which met the analyst consensus estimate. This is a 14.29 percent decrease over earnings of $0.07 per share from the same…
benzinga.com Earnings Scheduled For November 10, 2025 - benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session